OvaScience Appoints Paul W.D. Chapman To Chief Operating Officer

WALTHAM, Mass.--(BUSINESS WIRE)--OvaScience^SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced Paul W.D. Chapman has joined the Company as Chief Operating Officer. Mr. Chapman will be responsible for ensuring OvaScience’s treatments are available on a global commercial scale. He will serve on the executive management team of OvaScience and report to Dr. Michelle Dipp, M.D., Ph.D., Executive Chairman and Chief Executive Officer of OvaScience.

“As OvaScience ramps up commercial activities in 2016, we are diversifying our team to complement our strong scientific expertise with commercial and operational experience”

“As OvaScience ramps up commercial activities in 2016, we are diversifying our team to complement our strong scientific expertise with commercial and operational experience,” said Michelle Dipp, M.D., Ph.D., Executive Chairman and Chief Executive Officer of OvaScience. “With decades of experience behind him, Paul has proven his ability to develop and implement strategies across sales, marketing and business development capacities to global life sciences companies. I’m excited for Paul to join our leadership team as we grow our business and continue to expand access to our fertility treatments in select international markets.”

Mr. Chapman joins from ArjoHuntleigh AB, a Sweden-based leading acute and long-term care equipment company with global revenues of approximately $1 billion, where he served as Regional President of North America. In this role, Mr. Chapman turned around ArjoHuntleigh’s caregiver equipment business for patients with reduced mobility and implemented a comprehensive post-merger integration plan following parent company Getinge AB’s acquisition of Kinetic Concepts, Inc. Prior to this role, Mr. Chapman served as President and CEO of Massachusetts-based diagnostic company Quanterix, where he oversaw growth including closing a global licensing deal with BioMérieux and a Series C financing round of more than $45 million. Over the course of his more than 20-year career, Mr. Chapman has also held executive leadership roles at EMD Millipore, where he was Vice President of the Company’s BioPharm Process Solutions business, and the Roche Group, where he held multiple roles across different business areas including Hospital Solutions for Roche Near Patient Testing, Roche Molecular Diagnostics and Roche Diagnostics Canada. Mr. Chapman holds a B.S. degree in Microbiology from the University of Western Ontario, a B.S. (hons) in Immunology from the University of Guelph Ontario and he graduated from the Marketing Management Program from the Richard Ivey School of Business.

About OvaScience
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC^SM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT^SM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a non-commercial preceptorship training program with the OvaPrime^SM treatment, which could increase a woman’s egg reserve, and is developing the OvaTure^SM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S. For more information, please visit www.ovascience.com and www.augmenttreatment.com and connect with us on Twitter and Facebook.

Forward-Looking Statements
This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment, OvaPrime treatment and OvaTure treatment. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to provide or continue providing the AUGMENT treatment, or to delay such treatment based on clinical efficacy, safety or commercial, logistic, regulatory or other reasons; the science underlying our treatments (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval or licenses where necessary for our treatments; our ability to develop our treatments on the timelines we expect, if at all; our ability to commercialize our treatments, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

###